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ABSTRACT
ERBB2 receptor belongs to the ERBB tyrosine kinase receptor family. At variance 
to the other family members, ERBB2 is a constitutively active orphan receptor. Upon 
ligand binding and activation, ERBB receptors form homo- or hetero-dimers with the 
other family members, including ERBB2, promoting an intracellular signaling cascade. 
ERBB2 is the preferred dimerization partner and ERBB2 heterodimers signaling is 
stronger and longer acting compared to heterodimers between other ERBB members. 
The specific contribution of ERBB2 in heterodimer signaling is still undefined.
Here we report the formation of circular dorsal ruffles (CDRs) upon treatment 
of the ERBB2-overexpressing breast cancer cell lines SK-BR-3 and ZR751 with 
Trastuzumab, a therapeutic humanized monoclonal antibody directed against ERBB2. 
We found that in SK-BR-3 cells Trastuzumab leads to surface redistribution of ERBB2 
and ERBB1 in CDRs, and that the ERBB2-dependent ERK1/2 phosphorylation and 
ERBB1 expression are both required for CDR formation. In particular, in these 
cells CDR formation requires activation of both the protein regulator of actin 
polymerization N-WASP, mediated by ERK1/2, and of the actin depolymerizing protein 
cofilin, mediated by ERBB1. Furthermore, we suggest that this latter event may be 
inhibited by the negative cell motility regulator p140Cap, as we found that p140Cap 
overexpression led to cofilin deactivation and inhibition of CDR formation.
In conclusion, here we show for the first time an ERBB2-specific signaling 
contribution to an ERBB2/ERBB1 heterodimer, in the activation of a complex biological 
process such as the formation of CDRs.
INTRODUCTION
ERBB2 (Her2/Neu) is a member of the ERBB 
family of receptor tyrosine kinases (RTKs), which 
includes EGFR (ERBB1), ERBB3, and ERBB4. ERBB2 
is an orphan receptor and is the preferred dimerization 
partner for ERBB1, 3, and 4, upon their activation 
following the binding to specific ligands, e.g. EGF, TGF-α, 
and amphiregulin (for EGFR), or Heregulins/Neuregulins 
(for ERBB3/4) [1–3]. The oncogenic signaling by ERBB2 
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[4, 5] is thought to involve the sustained activation of a 
number of signaling pathways, including the Ras-Raf-
MAPK, which contributes to cell proliferation, and the 
PI3K-AKT, which induces cell survival [2, 6, 7].
Relative ratio of ERBB2/ERBB1 heterodimers on 
the plasma membrane varies among breast cancer cell 
lines; in the widely used SK-BR-3 line it was found to be 
approximately 3.2 [8]. However, the precise contribution 
of ERBB2 to the heterodimer signaling is not clear yet. In 
particular, evidence suggests that in the absence of ERBB2 
containing heterodimers, ERBB agonists elicited a weaker 
and curtailed signaling response [9].
The binding of the extracellular juxta-membrane 
region of ERBB2 to the therapeutic humanized 
monoclonal antibody Trastuzumab (Tz) [10, 11] in ERBB2 
overexpressing cells, results in the down regulation of the 
PI3K-AKT signaling, ERK1/2 activation in SK-BR-3 
cells [12], increased nuclear accumulation of the cell cycle 
inhibitor p27Kip1, and cell cycle arrest [13, 14]. At variance 
from earlier reports [15, 16], it is now opinion that 
endocytic down regulation of ERBB2 does not represent 
a relevant mechanism for signaling attenuation mediated 
by Tz [17, 18].
Circular dorsal ruffles (CDRs), also known as dorsal 
waves, are plasma membrane protrusions that merge in a 
single ring-shaped projection erecting vertically from the 
dorsal cell surface [19, 20]. These protrusions are formed as a 
result of the assembly of highly dynamic cortical actin-based 
structures in response to different growth factors [19, 21]. In 
contrast to other plasma membrane (PM) protrusions, CDRs 
are transient, and disappear usually within 5-30 min from the 
application of appropriate stimuli [22–24], such as ligands 
for several RTKs, ERBB1 included [19]. The formation of 
CDRs is, therefore, initiated by RTKs signaling and involves 
a complex array of reactions, since actin polymerization is 
induced by the Arp 2/3 activation by the Wiskott-Aldrich 
syndrome (WAS) family of proteins N-WASP and WAVE. 
Furthermore, activation of N-WASP is enhanced by ERK1/2-
dependent phosphorylation of cortactin [25, 26], an actin-
binding protein involved in polymerizarion of actin filaments 
necessary for the remodeling of actin cortical structures in 
CDR formation [19]. Moreover, cofilin, an actin-binding 
protein which disassembles actin filaments [27] and drives 
PM extension [28] might be implicated in CDR disassembly.
Although the functions of CDRs have not been 
conclusively clarified, it has been suggested that CDRs 
induce internalization of RTKs after ligand stimulation, 
macropinocytosis, and a rapid reorganization of the 
actin cytoskeleton preparing for cell motility [19, 29]. 
Despite cancer cells form less CDRs as compared to non 
transformed cells [19], CDR-related mesenchymal-like 
migration in 3-dimensional matrices has been associated 
with cancer metastasis [19], but their possible clinical 
relevance remains unclear.
In this study, we show that Tz treatment of the 
ERBB2-overexpressing breast cancer cells, promotes 
ERBB2/ERBB1 heterodimers and CDR formation. 
Taking advantage of this biological response, we identified 
and characterized two distinct and spatiotemporally 
coordinated ERBB2 and ERBB1 signaling pathways 
leading to CDR formation, thus dissecting the specific 
activity of ERBB2 in an ERBB2/ERBB1 heterodimer, in 
the absence of specific ERBB1 signaling.
RESULTS
Tz induces dramatic remodeling of the plasma 
membrane and circular dorsal ruffles formation
To characterize early events occurring at the level 
of the PM upon Tz binding to ERBB2, we analyzed the 
breast cancer cell line SK-BR-3, in a time range between 
2 and 120 min of treatment with Tz. ERBB1 and Tz-bound 
ERBB2 distribution was revealed by immunofluorescence 
on fixed cells, using antibodies directed to human IgGs and 
ERBB1, respectively (Figure 1). While in untreated SK-
BR-3 cells, ERBB2 and ERBB1 were mainly organized in 
clusters/patches at the cell periphery (Figure 1A), after 10 
min of Tz the two receptors co-redistributed in bona fide 
CDRs (Figure 1B), and displayed a diffuse distribution 
on the PM after 120 min of treatment (Figure 1C). As 
expected, a diffuse co-redistribution of ERBB2 and 
ERBB1 on the PM was also observed upon EGF treatment 
after 20 min when the percentage of cells showing CDRs 
is negligible or absent (Supplementary Figure 1).
The co-localization in SK-BR-3 cells of ERBB2 
with F-actin and with CDR markers such as cortactin 
and N-WASP:GFP chimera [34] confirmed that the 
observed structures were indeed CDRs (Figure 2A) as 
well as the colocalization of cortactin with F-actin and 
ERBB2 (Supplementary Figure 2). The percentage of 
cells displaying CDRs on their PM was significantly 
higher in the 10-15 min range of Tz treatment, compared 
to untreated cells (P<0.001 and P<0.0001, respectively) 
(Figure 2B). In our experimental setting, after 20 min of 
Tz treatment the percentage of cells showing CDRs was 
much reduced or negligible (Figure 2B). Similar results 
were obtained with an additional human breast cancer cell 
line named ZR751, which also overexpresses ERBB2, 
and showed colocalization of cortactin with F-actin and 
ERBB2 and a peak of CDR formation at 15 min followed 
by a decrease at 20 min of Tz treatment (Supplementary 
Figure 3).
Tz-induced CDRs depend upon ERK1/2 
activation
To investigate whether in our system CDRs 
represent a PM domain responsible for ERBB2 
endocytosis or a signaling platform, we first compared the 
internalization of this receptor with that of the transferrin 
receptor after transferrin binding by immunofluorescence 
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analysis. Our results showed that ERBB2 internalization 
upon Alexa555-Tz administration is negligible compared 
to that occurring to the Alexa488-transferrin (Figure 3). 
Therefore, we hypothesized that ERBB2 redistribution at 
the cell surface and CDR induction may be more related 
to signaling events rather than endocytosis.
Indeed, CDR formation is a complex event involving 
a signaling-mediated actin remodeling. Tz is known 
to promote the phosphorylation of the ERBB2 kinase 
domain, and ERK1/2 activation in SK-BR-3 cells [12]. 
To assess the timing of these events in our experimental 
context, control untreated and Tz-treated SK-BR-3 cell 
lysates were processed for Tz IP and immunoblot analysis. 
We observed that ERBB2 Tyr1248 phosphorylation 
increased progressively from 2 to 120 min (Figure 4A), 
whereas ERK1/2 phosphorylation showed a peak after 2 
min of Tz treatment (Figure 4B).
Since the ERK1/2 pathway is involved in actin 
nucleation, cytoskeleton reorganization [35], and 
activation of the cortactin-Arp2/3-N-WASP complex, 
involved in CDR formation [26], we tested whether the 
inhibition of the ERK1/2 activation would impair CDR 
formation induced by Tz. To this aim, we challenged the 
SK-BR-3 cells with the MEK1 specific inhibitor U0126, 
in combination with Tz, and scored the percentage of 
cells displaying CDRs. Under these conditions we 
detected a significantly lower fraction of cells displaying 
CDRs, after 10 min of treatment, compared to cells 
cultured in the absence of U0126 (Figure 4C). To assess 
whether ERBB2 interaction with N-WASP occurs after 
Tz treatment and depends from ERK1/2 activity, we 
performed co-IP studies in the absence and presence 
of U0126. The results revealed that the endogenous 
N-WASP co-immunoprecipitated with ERBB2 at 2 min 
(Figure 4D), whereas this association was lost after 20 
min, suggesting that the molecular machinery for CDR 
formation was transiently assembled at earlier time 
points of Tz treatment and mostly disassembled at 20 
min. Furthermore, we showed that the addition of U0126 
impaired N-WASP co-IP with ERBB2 (Figure 4D). 
Overall, these results show that Tz-induced ERK1/2 
signaling is necessary to promote CDR formation.
Figure 1: Trastuzumab (Tz) treatment modifies ERBB2 plasma membrane (PM) distribution and induces the formation 
of Circular Dorsal Ruffles (CDRs). SK-BR-3 control cells (NT) and SK-BR-3 cells treated with Tz at various time points, were 
fixed and immunostained for ERBB2 (green signal) and ERBB1 (red signal). Three different distribution patterns of PM ERBB2/ERBB1 
were recognized (A, B, C). Arrowheads indicate peripheral patches (A); arrows indicate CDRs (B), while (C) shows diffuse membrane 
localization. Scale bars = 10 μm. (B) Cortical dorsal ruffles (CDRs) were observed after 10 and 15 min of Tz treatment.
Oncotarget60112www.impactjournals.com/oncotarget
ERBB1 is necessary for CDR formation induced 
by Tz
As immunofluorescence data showed a complete co-
distribution of ERBB2 with ERBB1 in the CDRs, upon Tz 
treatment (Figure 1A), we decided to evaluate the specific 
contribution of the signaling downstream of either ERBB2 
or ERBB1 in the CDR formation process.
To this end, we silenced ERBB1 in SK-BR-3 by 
RNA interference, using the ERBB1 siRNA #1 (SK-
siERBB1) by RNA interference and observed a dramatic 
reduction of the percentage of cells displaying CDRs in the 
overall population of SK-siERBB1 compared to control 
SK-BR-3 cells (P<0.001) (Figure 5A). The impairment 
of CDR formation was even more evident when only 
those cells showing low expression or no expression at 
all of ERBB1 in the SK-siERBB1 cell population were 
taken into account (P<0.0001) (Figure 5A). Experiments 
performed using a different ERBB1 siRNA (ERBB1 
siRNA #2) yielded similar results (Supplementary Figure 
4) and we ruled out by immunofluorescence analysis that 
ERBB2 on the plasma membrane was lost in SK-siERBB1 
cells (Supplementary Figure 5). These results suggested 
that ERBB1 promotes CDR induction by Tz.
Figure 2: Cortactin and N-WASP are recruited on Circular Dorsal Ruffles (CDRs) that are transient PM structures 
induced by Trastuzumab (Tz). (A) SK-BR-3 were treated with Tz for 15 minutes, fixed and processed for immunofluorescence. (a) 
F-Actin stained with fluorescent phalloidin; (b) Cortactin revealed with a specific antibody; (c) N-WASP:GFP chimera revealed in the green 
channel; (d, e, f) ERBB2 detected with anti-ERBB2 antibody. Arrowheads indicate colocalization of F-actin, cortactin and N-WASP:GFP 
green signals with ERBB2 red signals in CDRs (g, h, i). Scale bars = 10 μm. (B) Quantification of Tz-induced CDR formation in SK-BR-3 
control cells (NT) and SK-BR-3 cells treated with Tz at various time points indicated in min. Bars represent the average ± SD of the data 
pooled from 3 independent experiments. At each time point at least 500 cells were analyzed.
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As we observed a strong dependence of CDR 
formation on ERK1/2 signaling induced by Tz, we 
investigated whether the activation of this pathway 
depended on ERBB1. We found that SK-siERBB1 cells 
and those transfected with a control scrambled siRNA, 
displayed the same pattern of ERK1/2 activation upon 
Tz treatment (Figure 5B, 5C), which was also similar to 
that displayed by WT SK-BR-3 (Figure 4B). These data 
suggested that ERBB1 cooperates with ERBB2 in the 
Tz-induced CDR formation in an ERK1/2-independent 
manner, and that ERBB2 is likely the main activator of 
the ERK1/2 signaling under these conditions. Figure 5D 
shows the extent of the ERBB1 expression inhibition 
obtained in our experimental conditions.
Overexpression of p140Cap recapitulates the 
inhibitory effect of ERBB1-depletion on CDR 
formation and induces inactivation of cofilin
It has been previously shown that ERBB1 activity 
is antagonized by p140Cap protein [36], an adaptor 
protein involved in actin remodeling [32], which co-
immunoprecipitates with ERBB1 [36]. In particular, 
p140Cap was described as an oncosuppressor acting as 
a negative regulator of cell motility and invasion [37], 
and ERBB2-mediated breast cancer progression [38]. 
To test the involvement of p140Cap in CDR formation 
induced by Tz, and its relationship with ERBB1 and 
ERBB2 signaling, we first evaluated the expression 
of p140Cap in WT SK-BR-3 and in SK-siERBB1 
by immunoblot analysis of whole cell lysates. This 
analysis revealed that p140Cap was expressed at a 
lower level in WT SK-BR-3, compared to SK-siERBB1 
(Supplementary Figure 6). Subsequently, we explored 
whether the p140Cap negative effect on CDR formation 
was due to its ability to induce cofilin phosphorylation 
as previously reported [39]. Indeed, by measuring the 
p-cofilin/cofilin ratio in p140Cap overexpressing SK-
BR-3 cells (p140oe) and mock-transduced cells by 
immunoblot analysis, we found that p140Cap enhanced 
cofilin phosphorylation thus inhibiting its activity 
(P<0.01) (Figure 6A, 6B).
Figure 3: Transferrin but not Tz induces receptor internalization within 120 min of treatment in SK-BR-3 cells. SK-
BR-3 cells were treated with Alexa555-conjugated Tz (red signal) and with Alexa488-conjugated transferrin (green signal), fixed and 
imaged by confocal microscopy at the indicate time points (upper left corner).
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Figure 4: Trastuzumab (Tz) induces ERBB2 phosphorylation and activation of ERK 1/2 signaling which is necessary 
for N-WASP binding and CDRs formation. (A) Control SK-BR-3 (NT) or Tz treated at different time points as indicated (in min) 
were harvested and Tz bound ERBB2 was immunoprecipitated and blotted to analyze the extent of Tyr 1248 phosphorylation. (B) ERK1/2 
phosphorylation (pERK1/2) levels were analyzed in total cell lysates and calnexin (CANX) was used as loading control. (C) SK-BR-3 
were treated with Tz (white bars) or with Tz along with the MEK inhibitor U0126 (black bars) and cells displaying CDRs were scored at 
each indicated time point. Bars represent the average ± SD of the data pooled from 3 independent experiments. At each time point at least 
500 cells were analyzed. (D) ERBB2 bound to Tz was immunoprecipitated and then endogenous N-WASP and ERBB2 were detected by 
western blot analysis in cells treated with Tz and/or with U0126 at various time points indicated in min.
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Figure 5: ERBB1 is crucial for the CDR formation. SK-BR-3 wt or SK-BR-3 cells transfected with the siRNA #1 (see Material and 
Methods) specific for ERBB1 (SK-siERBB1) were treated with Tz for various times as indicated (in min). (A) Histogram of the percentage 
of cells showing CDRs at each time point. Bars represent the average ± SD of the percentage of cells with CDRs, observed at each time 
point pooled from 3 independent experiments. At each time point at least 500 cells were analyzed. The analysis was performed in either 
the total population of SK-BR-3 and SK-siERBB1 (tot) or only on those SK-siERBB1 cells showing very low or no ERBB1 signal (low). 
(B) Immunoblot analysis of ErbB1 expression and ERK1/2 phosphorylation (pERK1/2) in SK-siERBB1 cells. (C) Immunoblot analysis 
of ERBB1 expression and ERK1/2 signaling in SK-BR-3 cells transfected with a control siRNA (SK-control siRNA). (D) Immunoblot 
analysis of ERBB1 expression in SK-siERBB1 and SK-control siRNA. Calnexin (CANX) was used as loading control.
Oncotarget60116www.impactjournals.com/oncotarget
To understand whether p140Cap interacted with 
ERBB2 in both SK-BR-3 WT and SK-siERBB1 cells, 
we performed co-IP analysis of the Tz-bound ERBB2 
and found an increased p140Cap-ERBB2 co-IP in SK-
siERBB1, compared to SK-BR-3 WT cells (Figure 6C).
To evaluate the effect of p140Cap in CDR 
formation, we generated SK-BR-3 cell lines 
overexpressing the protein and the relative controls, SK-
p140Cap overexpressing (SK-p140oe) and SK-mock 
transduced cells, respectively, and quantified the CDRs 
observed upon Tz treatment. These experiments showed a 
statistically significant reduction of the number of CDRs 
in SK-p140oe compared to SK-mock cells (P<0.05) after 
15 min of treatment (Figure 6D). To establish whether 
the inhibitory effect of p140Cap on CDR formation was 
due to modulation of ERK1/2 signaling, we investigated 
by immunoblot analysis the levels of pERK1/2 and 
found no major differences between p140Cap-oe and 
mock transduced cells (Figure 7). In view of these 
results, we suggest that p140Cap may exert its negative 
activity on CDR formation independently from the 
ERK1/2 signaling pathway and possibly through cofilin 
phosphorylation.
ERBB1 promotes Tz-induced CDR formation by 
inhibiting cofilin deactivation
As p140Cap overexpression inhibits CDR formation 
and cofilin activity by inducing its phosphorylation, we 
analyzed the phosphorylation status of cofilin in both 
SK-siERBB1 and SK-BR-3 control cells transfected 
with a scrambled RNA oligonucleotide. The level of 
Figure 6: p140Cap co-immunoprecipitates with ERBB2, its overexpression recapitulates the inhibitory effect of 
ERBB1-depletion on CDRs formation and induces cofilin phosphorylation. (A) SK-p140oe and SK-mock whole cell lysates 
were analyzed for p140Cap expression levels, cofilin phosphorylation (p-cofilin) and for total cofilin. (B) Histogram showing the ratio of 
phosphorylated/total cofilin as determined by immunoblot analysis in SK-mock and SK-p140oe cells. Bars represent the average ± SD of 
3 independent experiments. (C) ERBB2 in SK-BR-3 wild type (SK-WT) and SK-siERBB1 was immunoprecipitated with Tz and ERBB2 
and p140Cap were detected by immunoblot analysis. (D) Transduced SK-BR-3 cells overexpressing p140 (SK-p140oe) and SK-mock 
transduced cells were treated with Tz for various time points as indicated (in min) and the histogram showing the percentage of cells with 
CDRs at each time point. Histogram bars represent the average ± SD of the percentage of cells with CDRs, observed in 2 replicates. At each 
time point at least 500 cells were analyzed.
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phosphorylated cofilin (p-cofilin) increases progressively 
during Tz treatment, in both silenced and control cells. 
However, p-cofilin reached significantly higher levels in 
SK-siERBB1, compared to SK-BR-3 cells (Figure 8), 
thus suggesting that ERBB1 signaling promoted cofilin 
activity by inhibiting its phosphorylation. Overall, these 
data suggest that upon Tz treatment of SK-BR-3 cells, 
ERBB1 negatively controls cofilin phosphorylation, thus 
promoting the actin filament severing and remodeling 
necessary to control CDR formation.
To test whether cofilin phosphorylation is 
sufficient to impair CDR formation, we expressed a 
phosphomimetic S3E mutant of cofilin SK-BR-3 cells, 
and scored the number of CDRs induced by Tz treatment, 
compared to cells transfected with WT cofilin, in three 
pooled independent experiments. The data showed a 
significant (P=0.02) reduction of CDR formation in SK-
Figure 7: p140Cap does not induce ERK1/2 phosphorylation. Immunoblot analysis of ErbB2 expression and (pERK1/2) in SK-
p140oe and SK-mock cell lysates. Calnexin (CANX) was used as loading control.
Figure 8: ERBB1 depletion induces cofilin-1 phosphorylation, which inhibits CDRs formation. (A) SK-BR-3 wild type 
(SK-WT) or SK-BR-3 cells transfected with siRNA specific for ERBB1 (SK-siERBB1) were untreated (NT) or treated with Tz for various 
time points as indicated (in min) and harvested for IP and western blot analysis. Whole cell lysates were analyzed for cofilin phosphorylation 
(p-cofilin) and total cofilin levels (cofilin). GAPDH was used as loading control. (B) SK-BR-3 cells were transfected with a construct 
expressing wt cofilin or the S3E cofilin mutant. Histogram bars represent the average ± SD of the percentage of cells with CDRs, observed 
in 3 replicates. For each experiment at least 3000 cells were analyzed.
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BR-3 cells expressing the phosphomimetic S3E mutant 
(Figure 8B), compared to control cells. The expression 
of both cofilin WT and of the phosphomimetic S3E 
mutant was assessed by immunofluorescence analysis 
(Supplementary Figure 7).
Taken together, our results show that Tz-induced 
formation of transient CDRs depends on the activation of 
ERK1/2 signaling triggered by ERBB2 and on ERBB1-
mediated maintenance of cofilin activity.
DISCUSSION
Trastuzumab is a humanized antibody directed 
against ERBB2 that revolutionized the treatment of 
ERBB2 breast cancers [10]. The introduction of Tz therapy 
and, more recently, of the first successful ERBB2-targeted 
antibody–drug conjugate (ADC), trastuzumab emtansine 
(T-DM1, Kadcyla, Genentech) markedly improved 
the poor prognosis associated with ERBB2-amplified 
breast cancers [40] [41] [42]. Notwithstanding, as the 
very early signaling events generated by Tz in targeted 
cells are poorly studied, we performed biochemical and 
morphological analyses in the ERBB2 overexpressing 
breast cancer cell line SK-BR-3 to determine the ERBB2 
and ERBB1 signaling contribution in the context of an 
ERBB2/ERBB1 heterodimer. In particular, we observed 
that Tz induces CDR formation.
The formation of CDRs can be elicited by growth 
factors targeting RTKs [19]. Under these conditions, 
CDRs are proposed to act as spatially restricted signaling 
microdomains and as endocytic platform for receptor 
degradation [43]. Although CDRs significantly contribute 
to EGF-mediated ERBB1 internalization [37], here we 
observed poor ERBB2 internalization upon Tz-treatment 
as reported by others [17] [44]. These data support 
the hypothesis that Tz-induced CDRs may represent a 
transient but specific ERBB2/1 signaling platform in in 
vitro models. As little is known about the mechanism 
of their formation, it is important to determine the 
signaling pathways that are involved in Tz-induced CDR 
formation. N-WASP function, by binding to the RTK 
adaptor protein GRB2 [45], upstream of RAS-MEK 
mediated activation of ERK1/2, is critical for robust 
dorsal ruffles formation.
Here, we show for the first time that heterodimers 
formed by ERBB2/ERBB1 generates distinct signals, 
each necessary but not sufficient to induce the PM and 
cytoskeletal remodeling required for CDR formation. 
Firstly, we show that inhibition of the Tz dependent 
ERK1/2 phosphorylation via the MEK inhibitor 
U0126 impairs the N-WASP-ERBB2 interaction and 
the formation of CDRs. Because ERBB1 silencing is 
ineffective on ERK1/2 phosphorylation, we reason 
that this pathway only depends on the ERBB2 kinase 
activity. Secondly, we demonstrate that ERBB1 silencing 
completely abolished CDR formation, suggesting that a 
different ERBB1 signaling module is required for this 
process.
As actin-remodeling and the severing of pre-existing 
actin filaments are necessary for CDR formation, we 
concentrated our attention on a key protein that promotes 
these events, i.e cofilin [46]. The actin-severing activity 
of cofilin is inhibited by phosphorylation [47]. Indeed, 
we show that ERBB1 silencing increased the levels of 
p-cofilin, suggesting that the ERBB1 signaling module 
leading to CDR formation included maintenance of 
cofilin in a dephosphorylated and active status. The 
role of the cofilin/p-cofilin ratio in activating/inhibiting 
CDR formation upon Tz treatment was confirmed 
by the inhibition of CDR formation observed in cells 
overexpressing a cofilin phosphomimetic mutant.
We also suggest that the link between ERBB1 
signaling and cofilin activity may be the p140Cap 
oncosuppressor protein. Indeed, SK-BR-3 cells 
overexpressing p140Cap display a lower percentage of 
cells with CDRs and an increased level of p-cofilin in the 
absence of changes of ERK1/2 phosphorylation levels 
compared to controls. Therefore, it appears that p140Cap 
has an inhibitory role on cofilin activity, and eventually on 
the actin severing process necessary to CDR formation. As 
silencing of ERBB1 increases both the levels of p-cofilin 
and of p140Cap interaction with ERBB2, as demonstrated 
by co-IP assays, we suggest that upon Tz binding, the 
ERBB1 function in the ERBB2/ERBB1 heterodimer is 
to impair the p140Cap-mediated cofilin inactivation, by 
displacing p140Cap from ERBB2.
In conclusion, the integration of these distinct 
signaling pathways is required to generate a specific 
crosstalk that is necessary to promote CDR formation. 
These data represent the first identification of an ERBB2 
specific signaling activity in an ERBB heterodimer 
context.
MATERIALS AND METHODS
Cell culture and drug treatments
Breast cancer cell line SK-BR-3 and ZR751 were 
obtained from ATCC. SK-p140 and SK-mock transduced 
cell lines were developed by Dr. Paola Defilippi. Cells 
were cultured in DMEM, supplemented with 10% of 
fetal bovine serum, 1% glutamine and penicillin and 
streptomycin, at 37°C in a humidified atmosphere 
containing 5% CO2.
Tz (Genentech-Roche, South San Francisco, CA, 
USA) was dissolved with saline solution with 0.9%NaCl 
in a stock concentration of 20 mg/ml, donated by the 
pharmacy (UFA-Unità Farmaci Antiblastici) of the 
IRCCS AOU - San Martino - IST. Where indicated, Tz 
was used conjugated with Alexa-488 using the Alexa Fluor 
488 Protein Labeling Kit following the manufacturer's 
instructions (Molecular Probes, Eugene, OR, USA).
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In all the experiments, Tz was used in a 
concentration of 10 μg/ml [30]. Cells were treated with Tz 
in DMEM serum-free at 37°C. When indicated cells were 
treated with 100 ng/ml EGF or 1 mg/ml transferrin.
In ERK1/2 inhibition experiments, cells were pre-
incubated with 10μM U0126 (Promega, Madison, WI, 
USA), in DMEM serum-free at 37°C for 20 minutes, 
and maintained at the above concentration during the Tz 
treatment.
Immunofluorescence analysis
Cells were fixed in 3% paraformaldheyde (PFA) in 
phosphate-buffered saline (PBS) pH7.4 and then quenced 
with 30mM NH4Cl. After permeabilization with 0.2% 
saponin/PBS, Tz (10 μg/ml) or mouse monoclonal anti-
ERBB2 9G6 (sc-08, Santa Cruz, Santa Cruz, CA, USA) 
were used as primary antibody in cells followed by 
detection with an anti-human Cy2 and anti-mouse Cy2 or 
Cy3 antibodies, respectively.
The following primary antibodies were incubated 
for 20 min in 0.2% saponin/PBS: rabbit anti-cortactin 
(ab11066, Abcam, Cambridge, UK), mouse anti-ERBB1 
(Ab 108, kindly provided by IFOM). The secondary 
antibodies were incubated for 20 min in 0.2% saponin/
PBS: Cy3-conjugated donkey anti-mouse IgG (Jackons 
ImmunoResearch Laboratories, West Grove, PA, USA) 
and Alexa488-cojugated goat anti-human IgG (Molecular 
Probes). Where indicated, cells were treated with Tz 
conjugated with Alexa488 or Alexa555.
The F-actin staining was detected directly with 7μM 
Phalloidin-TRITC (P1951, Sigma-Aldrich, St. Louis, MO, 
USA) after cells fixation and permeabilization.
For nuclear staining, DAPI (Sigma) at 100 ng/ml 
was used for 5 min prior to mounting. The coverslips were 
mounted using Mowiol 4-88 reagent (Calbiochem, San 
Diego, CA, USA). Image acquisition was perfomed with 
an Olympus IX70 epifluorescence microscope. Images 
were captured under oil with a 63x plan apochromat 
objective. When indicated, images were acquired at 37°C 
with TCS-SP2 AOBS confocal microscope station (Leica 
Microsystems, Wetzlar, Germany).
Immunoprecipitation (IP) and western blot 
analysis
Protein cell extracts and SDS Polyacrylamide 
gel electrophoresis were performed using standard 
protocols [31]. Protein quantification was performed 
using Bradford protein assay (BioRad, Hercules, CA, 
USA). Tz administered to live starved cells (at 10μg/
ml of final concentration) for 2 min or 20 min (serum 
free medium) was used as a primary anti-ERBB2 
antibody. To immunoprecipitate ERBB2 from control Tz-
untreated and starved cells we first performed cell lysis 
and subsequently added Tz to the cell lysate (at 10μg/
ml of final concentration). Protein A-Sepharose CL-4B 
(GE Healthcare, Piscataway, NJ, USA) was added to the 
cell lysate to immunoprecipitate Tz bound to ERBB2. 
For ERBB1 IP, we used agarose-conjugated anti-EGFR 
(sc-03 AC, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA).
Samples were separated by SDS–PAGE and 
analyzed by immunoblotting, using as primary 
antibodies: rabbit anti-ERBB2 (c-18, sc-284, Santa 
Cruz), rabbit anti p-ERBB2 Y1248 (#2247; Cell 
Signaling Technology, Danvers, MA, USA), goat anti-
pERK1/2 (sc-16982, Santa Cruz), rabbit anti-calnexin 
(sc-11397, Santa Cruz), rabbit anti-GAPDH (#2118, 
Cell Signaling), mouse anti-cofilin (1G6A2, Proteintech, 
Rosemont, IL, USA), rabbit anti-p-cofilin (#3311, Cell 
Signaling), rabbit anti-cortactin (#3503, Cell Signaling), 
mouse anti-p140Cap (generated by Dr. Paola Defilippi’s 
laboratory) [32]. Secondary antibodies were horseradish 
peroxidase-conjugated: anti-mouse (Molecular Probes, 
Thermo Fisher Scientific, Waltham, MA, USA), anti-
rabbit (Molecular Probes) and anti-goat (Santa Cruz) 
and the detection of proteins were performed with ECL 
Detection Reagent (GE Healthcare).
Densitometric analysis of western blots was 
performed with ImageJ Gel Analysis software.
RNA interference
SK-BR-3 cells were transiently transfected with two 
siRNA Stealth oligos (Invitrogen, Carlsbad, CA, USA) 
anti-ERBB1:#1 (5’-CCGCAGCAUGUCAAGAUCAC
AGAUU-3’), and #2 (5’-CCACCGUGGCUUGCAUUG
AUAGAAA-3’) using Lipofectamine 2000 accordingly 
to the manufacturer’s instructions (Invitrogen). All the 
experiments were performed using cells transfected with a 
scrambled (SCR) oligo as control (5’-CCGACGUGUAAC
UAGCACGACAAUU-3’). Briefly, cells were subjected to 
two rounds of transfection, 24 and 48 hours after plating, 
and were treated and processed 72 hours after the first 
round of transfection.
Transfection of expression vectors
Construct transfections were performed using 
Lipofectamine 2000, accordingly to the manufecturer’s 
instructions (Invitrogen). Constructs employed in this 
study were: a N-WASP:GFP chimera [33] and the 
pmRFP-N1 human cofilin WT and S3E, which were 
acquired from Addgene (plasmid # 50856 and # 50858, 
Cambridge, MA, USA).
Localization of N-WASP:GFP in epifluorescent 
microscopy was performed 48h after cell transfection 
while CDRs were analyzed in cofilin WT:RFP and 
cofilin S3E:RFP chimera expressing cells 18h after 
transfection.
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ERBB2 plasma membrane redistribution and 
Circular Dorsal ruffling assay and statistical 
analysis
To analyze the number of cells showing a single 
CDR two observers evaluated slides independently and 
at least 500 cells, for each experimental condition, were 
analyzed. All parameters measured are presented as mean 
± standard deviation and were analyzed with the Student’s 
t-test using a two-tailed distribution. P values < 0.05 were 
considered statistically significant.
Abbreviations
Tz, Trastuzumab; RTKs, receptor tyrosine kinases; 
PM, plasma membrane; CDR, circular dorsal ruffle; IP, 
immunoprecipitation; GFP, green fluorescent protein.
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